144 related articles for article (PubMed ID: 17008892)
1. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892
[No Abstract] [Full Text] [Related]
2. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
3. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C
Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211
[No Abstract] [Full Text] [Related]
4. Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Popovici C; Charbonnier A; Gisserot O; Aguilon P; Rémy V; Olschwang S; Mozziconacci MJ
Leuk Res; 2008 Feb; 32(2):361-2. PubMed ID: 17412419
[No Abstract] [Full Text] [Related]
5. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
[TBL] [Abstract][Full Text] [Related]
6. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
[TBL] [Abstract][Full Text] [Related]
7. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib.
Khorashad JS; Anand M; Marin D; Saunders S; Al-Jabary T; Iqbal A; Margerison S; Melo JV; Goldman JM; Apperley JF; Kaeda J
Leukemia; 2006 Apr; 20(4):658-63. PubMed ID: 16467863
[TBL] [Abstract][Full Text] [Related]
8. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
9. Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
[No Abstract] [Full Text] [Related]
10. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
11. New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
[TBL] [Abstract][Full Text] [Related]
12. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
[No Abstract] [Full Text] [Related]
13. Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.
Corm S; Biggio V; Roche-Lestienne C; Laï JL; Yakoub-Agha I; Philippe N; Nicolini FE; Facon T; Preudhomme C
Leukemia; 2005 Nov; 19(11):1991-2. PubMed ID: 16151468
[No Abstract] [Full Text] [Related]
14. Resistance and relapse with imatinib in CML: causes and consequences.
Deininger M
J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S11-S21. PubMed ID: 18397677
[TBL] [Abstract][Full Text] [Related]
15. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
Tauchi T; Oyashiki K
Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
[No Abstract] [Full Text] [Related]
16. BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?
Gruber FX; Lundán T; Goll R; Silye A; Mikkola I; Rekvig OP; Knuutila S; Remes K; Gedde-Dahl T; Porkka K; Hjorth-Hansen H
Med Oncol; 2012 Mar; 29(1):219-26. PubMed ID: 21221851
[TBL] [Abstract][Full Text] [Related]
17. Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene.
Janssen JJ; Hochhaus A; van Oostveen JW; Waisfisz Q; Schuurhuis GJ; Ossenkoppele GJ
Leukemia; 2004 May; 18(5):1020-1. PubMed ID: 15014529
[No Abstract] [Full Text] [Related]
18. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
19. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
20. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
[Next] [New Search]
